Nearly Half Of Indian Healthcare, Pharma Firms Plan To Integrate Gen AI Within A Year: EY
The Indian healthcare and life sciences sector—which has traditionally been conservative in adopting digital technologies—is witnessing a gradual shift, according to an EY survey report, with 60% of survey participants saying generative artificial intelligence will have a significant impact on the entire value chain.
While 28% of healthcare and life sciences firms in India have already implemented their first Gen AI solution, 48% plan to implement it within one year.
In healthcare, Gen AI has the potential to benefit different facets of the value chain, including clinical services, customer operations and branding. In life sciences, integrating Gen AI can expedite the assimilation of technologies across the value chain.
Suresh Subramanian, partner and national life sciences leader, EY Parthenon India, said, “While the Indian life sciences enterprises initially exercised caution regarding AI adoption, numerous Gen AI applications are now contributing to drug development and highly targeted therapies, which is likely to put India in the global clinical trial map.”
“There is a likely fast followership by pharma and medical devices in Gen AI in customer acquisition, delivering personalised care, patient experience and outcomes, process optimisation across value chain, such as supply and demand planning and operational efficiency, to enhance overall productivity,” Subramanian added.
While some organisations in India are already piloting Gen AI in controlled environments, 80% of the surveyed firms acknowledged that their organisations are not yet fully prepared to adopt this technology. Nevertheless, there is interest in establishing Gen AI infrastructure.
“In an environment marked by significant demand supply disparities and a shortage of clinical and non-clinical talent (e.g., only 64 doctors per 100,000 patients compared to the global average of 150 per 100,000), Gen AI holds the potential to augment the healthcare system's capabilities and accelerate transformation of diagnostics, treatments and patient care,” said Kaivaan Movdawalla, healthcare leader, EY Parthenon India.
While concerns revolve around potential job displacements, surveyed leaders were positive that Gen AI will not replace the core healthcare workforce but improve their efficiency and release more supply in the healthcare system. While 84% said Gen AI can positively impact workforce productivity, 60% believed it could amplify workforce potential.
However, healthcare and pharma leaders cautioned that the adoption and implementation of Gen AI would be challenging. Apprehensions among industry leaders include lack of adequate skills and understanding within the existing ecosystem and reservations regarding result accuracy. Concerns pertaining to data privacy, cybersecurity and the potential for biased responses underscore the need to address these challenges before adopting Gen AI.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.